Category

AIM Investors

Result of GM

By AIM Investors
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that all resolutions put to shareholders at the Company's General Meeting held earlier today were duly passed. Company Contacts Motif Bio plc Graham Lumsden, Chief Executive Officer info@motifbio.com Zeus Capital Limited (Nominated Advisor and Broker) Phil Walker / Giles Balleny Dominic Wilson +44 (0) 20 3829 5000 Northland Capital Partners Limited (Broker) Patrick Claridge / David Hignell John Howes / Rob Rees (Broking) +44 (0) 207 382 1100 Walbrook PR Ltd. (Public and Investor Relations) Paul McManus / Mike Wort Main: +44 (0)20 7933 8780 Paul: +44 (0)7980 541 893 Mike: +44 (0)7900 608 002 motifbio@walbrookpr.com MC Services AG (European IR) Raimund Gabriel +49 (0) 89 210 2280
Read More

Publication of Circular and Notice of General Meeting

By AIM Investors
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on Friday 2 December 2016 it sent to Shareholders a circular and notice of General Meeting to be held at the offices of Reed Smith LLP at The Broadgate Tower, 20 Primrose Street, London EC2A 2RS on 21 December 2016 at 2.00 p.m. at which the following Resolutions will be proposed: Resolution 1, which will be proposed as an ordinary resolution, is to authorise the Directors to allot relevant securities up to an aggregate nominal value of £313,938.23 in connection with the exercise of various share options, warrants and convertible securities granted by the Company between 1 April 2015 and the date of...
Read More

Issue of Equity and Total Voting Rights

By AIM Investors
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has issued 119,990 new ordinary shares in the Company (“Ordinary Shares”) as a result of the exercise of options. Application has been made for the 119,990 new Ordinary Shares to be admitted to trading on AIM (“Admission”), which is expected to occur at 8.00 a.m. on 6 December 2016. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 180,763,734 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine...
Read More